There is only one endogen inhibitor of ADAM-17, known as tissue inhibitor of metalloproteinase 3 (TIMP3), which activity is reduced in obesity, atherosclerosis, diabetes and insulin resistance (Chavey et al., 2003; Cardellini et al., 2009, 2011; Menghini et al., 2013). Here, TIMP3 is linked to diabetes mellitus.